Human papillomavirus‐related oropharyngeal cancer in the <scp>HIV</scp>‐infected population

Abstract

Human papillomavirus ( HPV ) is a common sexually transmitted virus and an important etiologic factor in head and neck cancers. HIV ‐infected individuals are at increased risk of developing oropharyngeal cancers ( OPC ) compared with the general population. HPV ‐positive OPC are also increasingly a significant cause of morbidity and mortality for HIV ‐infected individuals in the era of effective combination antiretroviral therapy. The epidemiology and natural history of oral HPV infection have not been well established, but it appears that oral HPV infection is less common than anal infection, and more common among HIV ‐infected persons than the general population. Prevention of OPC is therefore increasingly important in HIV ‐infected individuals. Although not demonstrated in randomized controlled trials, HPV vaccination may prevent oral HPV infection as well. The focus of organized HPV cancer prevention programs should include prophylactic HPV vaccination to reduce the burden of high‐risk HPV and low‐risk HPV types who have not yet been exposed.